ICD-10 Code D70.1 | Agranulocytosis secondary to cancer chemotherapy Symptoms, Diagnosis, Billing

Agranulocytosis secondary to cancer chemotherapy is a severe reduction in neutrophils, often resulting from cytotoxic agents used in cancer treatment. This condition is clinically significant as it increases the risk of infections, necessitating accurate diagnosis and documentation. The ICD-10 Code D70.1 facilitates precise medical billing and public health reporting, ensuring that healthcare providers can effectively manage and treat affected patients.

What is ICD-10 Code D70.1 for Agranulocytosis secondary to cancer chemotherapy?

ICD-10 Code D70.1 represents agranulocytosis that occurs as a complication of cancer chemotherapy. This condition is characterized by a dangerously low level of neutrophils, which can lead to severe infections. The code should be used in clinical documentation and billing when a patient presents with this condition following chemotherapy treatment, ensuring appropriate care and resource allocation.

ICD-10 Code D70.1 – Clinical Definition and Explanation of Agranulocytosis secondary to cancer chemotherapy

Agranulocytosis secondary to cancer chemotherapy is primarily caused by the myelosuppressive effects of chemotherapeutic agents, leading to a significant decrease in neutrophil production. This condition requires immediate medical attention due to the heightened risk of infections and potential complications.

Key Clinical Features:

• Severe neutropenia (absolute neutrophil count < 500 cells/mm³)
• Increased susceptibility to bacterial and fungal infections
• Fever and signs of infection, such as chills or malaise
• Potential for life-threatening complications if untreated

ICD-10 Code D70.1 for Agranulocytosis secondary to cancer chemotherapy – SOAP Notes & Clinical Use

ICD-10 Code D70.1 is utilized in SOAP notes to document the presence of agranulocytosis following chemotherapy. It plays a crucial role in capturing patient symptoms, assessments, and treatment plans, relevant in both acute and chronic care settings.

What Does ICD-10 Code D70.1 for Agranulocytosis secondary to cancer chemotherapy Mean in SOAP Notes?

In SOAP notes, ICD-10 Code D70.1 connects subjective patient-reported symptoms and objective clinical findings to a formal diagnosis of agranulocytosis. This ensures continuity of care, supports accurate billing, and meets EHR documentation standards.

Treatment Options for ICD-10 Code D70.1 – Agranulocytosis secondary to cancer chemotherapy

Agranulocytosis secondary to cancer chemotherapy often necessitates hospitalization for close monitoring and treatment. Prompt intervention is critical to prevent severe infections.

Antibiotic Therapy:

• First-line: Broad-spectrum antibiotics such as piperacillin-tazobactam or cefepime, typically for 7-14 days.
• Alternative: Carbapenems for resistant infections, duration based on clinical response.

Supportive Care:

• Granulocyte colony-stimulating factor (G-CSF) to stimulate neutrophil production.
• Transfusions if indicated for severe anemia or thrombocytopenia.
• Hydration and nutritional support as needed.

Infection Control:

• Strict hand hygiene and use of personal protective equipment (PPE).
• Isolation precautions to prevent exposure to infectious agents.
• Monitoring for signs of infection and prompt intervention.

How to Document Symptoms of Agranulocytosis secondary to cancer chemotherapy (ICD-10 D70.1) in SOAP Notes

Subjective:

• Patient reports fever and chills over the past 48 hours.
• History of recent chemotherapy treatment.
• Complaints of fatigue and malaise.
• No known allergies reported.

Objective:

• Vital signs: Temperature 101°F, heart rate 110 bpm.
• Laboratory results: Absolute neutrophil count < 500 cells/mm³.
• Physical exam: Signs of infection, such as erythema or swelling.
• No lymphadenopathy noted.

Secure, compliant, and built for trust

HIPAA-compliant and designed with privacy in mind, your patient’s data is protected. Focus on care while we safeguard your information.

Learn more

SOAP Note Guidelines for Diagnosing Agranulocytosis secondary to cancer chemotherapy (ICD-10 Code D70.1)

Assessment:

• Diagnosis: Agranulocytosis secondary to cancer chemotherapy, severe.
• ICD-10 Code: D70.1.
• Contributing factors: Recent chemotherapy treatment.
• Monitor for potential infections.

Plan:

• Initiate broad-spectrum antibiotic therapy.
• Administer G-CSF as indicated.
• Educate patient on signs of infection and when to seek care.
• Schedule follow-up in 1 week or sooner if symptoms worsen.

Treatment & Plan Section for ICD-10 Code D70.1 – Agranulocytosis secondary to cancer chemotherapy

• Administer appropriate antibiotics based on culture results.
• Provide supportive care including hydration and nutritional support.
• Monitor blood counts regularly to assess recovery.
• Educate patient on infection prevention strategies.

Using ICD-10 Code D70.1 for Agranulocytosis secondary to cancer chemotherapy in Billing & SOAP Note Compliance

• Ensure accurate documentation of symptoms and clinical findings in SOAP notes.
• Use D70.1 in conjunction with relevant treatment codes for billing.
• Document any complications or additional diagnoses clearly.
• Align treatment plans with clinical guidelines to support justified billing.

Related ICD-10 Codes Often Used with Agranulocytosis secondary to cancer chemotherapy

• D70.0 – Agranulocytosis, unspecified
• D70.2 – Agranulocytosis due to other drugs

ICD-10 Code D70.1 in Medical Billing and Insurance for Agranulocytosis secondary to cancer chemotherapy

ICD-10 Code D70.1 is essential for accurate billing in hospital, ER, or infectious disease care settings.

Billing Notes:

• Document all relevant clinical findings and treatment plans to support the claim.
• Use D70.1 in conjunction with other codes for comprehensive billing.
• Ensure that the diagnosis is clearly linked to the patient's treatment history.

Common CPT Pairings: